Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 1
Submit an article Journal homepage
200
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Prognostic significance of serum β2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified

Hyung-Don Kima Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of KoreaORCID Iconhttps://orcid.org/0000-0001-9959-0642
ORCID Icon,
Hyungwoo Choa Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
,
Byeong Seok Sohnb Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Busan, South Korea
,
Chan-Sik Parkc Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
,
Jooryung Huhc Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
,
Jin Sook Ryud Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
,
Sang-Wook Leee Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
,
Sang Eun Yoonf Division of Hematology Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
,
Seok Jin Kimf Division of Hematology Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
,
Young Hyeh Kog Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
,
Won Seog Kimf Division of Hematology Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaORCID Iconhttps://orcid.org/0000-0002-5400-0466
ORCID Icon &
Cheolwon Suha Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of KoreaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9178-4431
ORCID Icon show all
Pages 124-130 | Received 08 Jun 2021, Accepted 15 Aug 2021, Published online: 26 Oct 2021

References

  • Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
  • Broccoli A, Zinzani PL. Peripheral T-cell lymphoma, not otherwise specified. Blood. 2017;129(9):1103–1112.
  • Carson KR, Horwitz SM, Pinter-Brown LC, et al. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer. 2017;123(7):1174–1183.
  • Iqbal J, Weisenburger DD, Greiner TC, et al.; International Peripheral T-Cell Lymphoma Project. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026–1036.
  • Iqbal J, Wright G, Wang C, et al.; Lymphoma Leukemia Molecular Profiling Project and the International Peripheral T-cell Lymphoma Project. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915–2923.
  • Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98(8):e81–e82.
  • Bossard C, Dobay MP, Parrens M, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124(19):2983–2986.
  • A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987–994.
  • Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–2479.
  • Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472–2479.
  • Vose JM, Project IP. International peripheral T-Cell lymphoma (PTCL) clinical and pathologic review project: Poor outcome by prognostic indices and lack of efficacy with anthracyclines. Am Soc Hematol. 2005;26(25):4124–4130.
  • Federico M, Bellei M, Marcheselli L, et al.; the T cell Project Network. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). Br J Haematol. 2018;181(6):760–769.
  • Chronowski GM, Wilder RB, Tucker SL, et al. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer. 2002;95(12):2534–2538.
  • Yoo C, Yoon DH, Jo JC, et al. Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma. Ann Hematol. 2014;93(6):995–1000.
  • Yoo C, Yoon DH, Yoon S, et al. Prognostic impact of β2-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma. 2015;56(3):688–693.
  • Kim HD, Cho H, Jeong H, et al. A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue international prognostic index and serum β2-microglobulin levels. Br J Haematol. 2021;193(2):307–315.
  • Kim HD, Cho H, Kim S, et al. Prognostic stratification of patients with burkitt lymphoma using serum β2-microglobulin levels. Cancer Res Treat. 2021;53(3):847–856.
  • Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–4562.
  • López-Guillermo A, Colomo L, Jiménez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol. 2005;23(12):2797–2804.
  • Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al. The prognostic significance of beta(2)-microglobulin in patients with hodgkin's lymphoma. Haematologica. 2002;87(7):701–708.
  • Constantinides IP, Pathouli C, Karvountzis G, et al. Serum β2 microglobulin in malignant lymphoproliferative disorders. Cancer. 1985;55(10):2384–2389.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.